Genomic Health, Inc. (NASDAQ:GHDX) insider Phillip G. Febbo sold 3,174 shares of the company’s stock in a transaction that occurred on Wednesday, July 19th. The shares were sold at an average price of $33.57, for a total value of $106,551.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Genomic Health, Inc. (GHDX) traded down 1.43% during trading on Friday, reaching $29.59. The company had a trading volume of 91,229 shares. Genomic Health, Inc. has a 12-month low of $25.66 and a 12-month high of $33.97. The firm’s 50 day moving average price is $31.85 and its 200 day moving average price is $31.25. The firm’s market capitalization is $1.03 billion.
Genomic Health (NASDAQ:GHDX) last posted its earnings results on Tuesday, August 1st. The medical research company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by $0.02. Genomic Health had a negative return on equity of 4.33% and a negative net margin of 1.50%. The company had revenue of $85.50 million during the quarter, compared to the consensus estimate of $86.08 million. During the same period last year, the firm posted ($0.18) EPS. The company’s revenue for the quarter was up 4.3% on a year-over-year basis. Equities research analysts forecast that Genomic Health, Inc. will post ($0.01) EPS for the current year.
Large investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in Genomic Health by 6.8% in the second quarter. Vanguard Group Inc. now owns 1,670,622 shares of the medical research company’s stock worth $54,379,000 after buying an additional 106,452 shares during the period. Columbia Wanger Asset Management LLC increased its stake in Genomic Health by 26.1% in the first quarter. Columbia Wanger Asset Management LLC now owns 1,607,649 shares of the medical research company’s stock worth $50,625,000 after buying an additional 332,311 shares during the period. Renaissance Technologies LLC increased its stake in Genomic Health by 10.9% in the second quarter. Renaissance Technologies LLC now owns 813,300 shares of the medical research company’s stock worth $26,473,000 after buying an additional 80,100 shares during the period. Loomis Sayles & Co. L P increased its stake in Genomic Health by 10.0% in the first quarter. Loomis Sayles & Co. L P now owns 584,515 shares of the medical research company’s stock worth $18,406,000 after buying an additional 53,344 shares during the period. Finally, State Street Corp increased its stake in Genomic Health by 6.6% in the fourth quarter. State Street Corp now owns 545,119 shares of the medical research company’s stock worth $16,024,000 after buying an additional 33,975 shares during the period. 88.54% of the stock is owned by institutional investors and hedge funds.
Several equities analysts have recently issued reports on GHDX shares. Jefferies Group LLC upped their target price on Genomic Health from $29.00 to $33.00 and gave the company a “hold” rating in a report on Wednesday, May 10th. Raymond James Financial, Inc. reaffirmed a “market perform” rating on shares of Genomic Health in a report on Wednesday, May 3rd. They noted that the move was a valuation call. Zacks Investment Research lowered Genomic Health from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $31.00 target price on shares of Genomic Health in a report on Thursday, August 3rd. Finally, BidaskClub downgraded Genomic Health from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $32.00.
About Genomic Health
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.